Shasqi prides itself on being a company of many firsts. The biotech hails from Y Combinator and was the first of the startup accelerator's offshoots to focus on therapeutics—and to enter human trials. Overall, the company claims to be first to advance a click-chemistry-based therapy into humans.
Now, Shasqi has collected $50 million in a series B financing to fuel the path through the clinic.
